Use of Ganciclovir in the Treatment of Acquired Cytomegalovirus Disease in a Preterm Infant | Zendy

H Amin | Zendy; Taj Jadavji | Zendy; Reginald S. Sauve | Zendy; M. John Gill | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of Ganciclovir in the Treatment of Acquired Cytomegalovirus Disease in a Preterm Infant

Author(s) -

H Amin,

Taj Jadavji,

Reginald S. Sauve,

M. John Gill

Publication year - 1990

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/1990/917057

Subject(s) - ganciclovir , medicine , cytomegalovirus , adverse effect , pediatrics , gestational age , cytomegalovirus infection , human cytomegalovirus , pregnancy , immunology , herpesviridae , viral disease , virus , biology , genetics

The first use of ganciclovir in a preterm infant is reported. The 27 week appropriate-for-gestational-age male infant developed a disseminated cytomegalovirus infection subsequent to a blood transfusion. A daily dose of 10 mg/kg administered intravenously in two divided doses for a total of 14 days was given without adverse clinical or toxic effects. The patient has remained well following discharge from hospital.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research